Simulated Cell / Virtual Lab

Turbine is an AI-powered virtual biology platform designed to accelerate drug discovery and enhance clinical translatability for biopharma partners. By virtualizing biological experiments through its Simulated Cell and Virtual Lab technologies, Turbine enables research and development teams to run millions of in silico experiments rapidly, generate mechanistic hypotheses, and make evidence-based decisions across the full drug discovery and development pipeline.

The platform is built for life sciences organizations seeking to reduce timelines, increase the probability of experimental validation, and gain deeper mechanistic understanding of biological systems — from early target discovery through to clinical positioning and indication expansion.

Key Performance Capabilities

• Simulate up to 50 million experiments per day, compressing what would take months into hours
• Mechanistic hypotheses generated by simulations deliver a 1.5x increase in the likelihood of wet lab validation success
• Timeline from scientific question to the start of validation is halved, enabling 2x faster progression
• Simulations act as a mechanism engine, revealing not just what occurs but why it occurs
• Every decision is grounded in evidence, boosting overall efficiency and probability of success

Drug Discovery Use Cases

• Target Discovery — identify and de-risk novel drug targets, including those with first-in-class potential
• Combination Design — simulate and evaluate combination therapy strategies in silico
• ADC Positioning — select and position antibody-drug conjugate payloads using the dedicated ADC Payload Selector tool
• Biomarker Selection — identify relevant biomarkers to support precision medicine approaches
• Clinical Positioning — inform clinical strategy with biology-driven insights at scale
• Indication Expansion — explore new therapeutic indications across a portfolio

Virtual Lab Tiers and Features

• vLab Core — self-serve access to simulations on public and Turbine's proprietary datasets, including over 1,400 oncology cell lines, 1,200 payloads, drugs and drug-like molecules, and knockout alterations across more than 8,500 genes; includes a robust interpretation toolkit for filtering and analysis of in silico results
• vLab Custom — in silico predictions leveraging a partner's own proprietary datasets combined with Turbine expertise; supports addition of custom sample libraries, proprietary drugs, and includes interpretation services
• vLab Collaborate — simulations on virtual endogenous disease models to enhance R&D decision-making across a portfolio; supports single or multi-cell samples of most endogenous diseases, any relevant chemical or biological therapies, and a simulations platform adapted to specific use cases with collaborative analysis and interpretation of results

Workflow Integration and Validation

• The platform adapts to partner needs, ranging from self-serve usage to deep workflow integration
• A wet lab-in-the-loop approach ensures that in silico predictions are validated in the wet lab, with resulting experimental data incorporated back into the Virtual Lab to continuously improve simulation predictivity
• Dedicated tools available within the Virtual Lab include the ADC Payload Selector, Target Discovery and De-Risking module, and the ability to simulate any endogenous disease

Turbine works with leading biopharma partners and is backed by investors including MSD Global Health Innovation Fund and Accenture Ventures. Partners such as Ono Pharmaceutical have leveraged the platform to identify first-in-class targets with biology-driven validation insights, underscoring Turbine's role as a transformative tool in precision oncology and broader drug discovery workflows.